P002. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalizations for heart failure in patients with or without diabetes. More evidence is needed regarding their effects across the broad spectrum of heart failure, including those with reduced ejection fraction (HFrEF).

Source: Heart and Lung - June 5, 2021 Category: Intensive Care Authors: Butler Javed, Stefan Anker, Martina Brueckmann, Gerasimos Filippatos, Waheed Jamal, Karen Kimura, Milton Packer, Stuart Pocock, Janet Schnee, Faiez Zannad, Cordula Zeller Tags: Research Source Type: research